



For immediate release 07.00: 28 August 2013

RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")

CONTRACT WIN

Retroscreen Virology Group plc (AIM: RVG), the viral challenge and "virometrics" specialist, is pleased to announce the signing of a new Viral Challenge Model ("VCM") contract with a global biopharmaceutical company for the provision of an influenza challenge study, with the contract valued at £2.0 million.

Kym Denny, Chief Executive Officer, commented, "It is really pleasing to see the continued expansion of our business development pipeline, which is now delivering excellent conversions to main contract signatures. We are seeing a sustained heightened level of interest in Retroscreen's VCM, with the model's ability to accelerate the drug and vaccine proof of concept decision-making process significantly. We have put a great deal of effort into building strong client relationships, so it is even more satisfying to note that this is the second contract signature in the course of a few days."

For further information please contact:

Retroscreen Virology Group plc +44 207 756 1300

Kym Denny (CEO)
Graham Yeatman (FD)

Numis Securities Limited +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)